Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

Fertility and Sterility

Volumn 76, Issue 1, 2001, Pages 13-24

  Lobo, Rogerio A ^a   Bush, Trudy ^b   Carr, Bruce R ^c   Pickar, James H ^d  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WYETH AYERST RESEARCH   (United States)

Author keywords

Carbohydrate metabolism; Coagulation; Conjugated equine estrogens (CEE); Hormone replacement therapy (HRT); Lipids; Lipoproteins; Lower doses; Medroxyprogesterone acetate (MPA); Women's HOPE study

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 8; CONJUGATED ESTROGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD CLOTTING; CARBOHYDRATE METABOLISM; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; ANIMALS; BLOOD COAGULATION FACTORS; CARBOHYDRATE METABOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HORSES; HUMANS; LIPIDS; LIPOPROTEINS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE;

EID: 0034950083     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)01829-5     Document Type: Article

References (50)

1. Healthcare use among U.S. women aged 45 and older; total costs and costs for selected postmenopausal health risks
2. Is there a menopausal metabolic syndrome?
3. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women
4. Impact of menopause on metabolism
5. Plasma cholesteryl ester fatty acid composition, insulin sensitivity, the menopause and hormone replacement therapy
6. Lipids, clotting factors, and diabetes; endogenous risk factors for cardiovascular disease
7. AHA/ACC scientific statement; consensus panel statement. Guide to preventive cardiology in women
8. Menopause and risk of cardiovascular disease. The Framingham Study
9. Metabolic risk factors for coronary heart disease in women; perspective from the Framingham Study
10. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
11. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women
12. Effect of postmenopausal hormone therapy on glucose and insulin concentrations
13. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women
14. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women; relation to their insulinemic secretion
15. Hormone replacement therapy with dydrogesterone and 17β-oestradiol; effects of serum lipoproteins and glucose tolerance during 24 month follow up
16. HRT in the prevention and treatment of osteoporosis
17. The role of hormone replacement therapy in the prevention of postmenopausal heart disease
18. Hormone replacement therapy in the prevention and treatment of atherosclerosis
19. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
20. Postmenopausal hormone therapy and mortality
21. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
22. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
23. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
24. Patient compliance of women taking estrogen replacement therapy
25. Continuation of postmenopausal hormone replacement therapy; comparison of cyclic versus continuous combined schedules
26. Determinants of long-term hormone replacement therapy and reasons for early discontinuation
27. Personal perspective on low-dosage estrogen therapy for postmenopausal women
28. Venous thrombo-embolism and hormone replacement therapy
29. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate
30. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol
31. Measurement of low-density lipoprotein cholesterol
32. Measurement and clinical significance of high-density lipoprotein cholesterol subclasses
33. Expressed hypervariable polymorphism of apolipoprotein (a)
34. Plasma lipoprotein levels as predictors of cardiovascular death in women
35. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women
36. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
37. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). A randomized controlled trial
38. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop
39. Lipoprotein(a) as a risk factor for coronary artery disease
40. Effect of postmenopausal hormone replacement therapy on lipoprotein(a) concentration
41. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause
42. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women
43. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
44. Cardiovascular implications of the factor V Leiden mutation
45. Factor V Leiden mutation and the risks for thromboembolic disease; a clinical perspective
46. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
47. Menopause-related changes in lipoproteins and some other cardiovascular risk factors
48. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding